Brian P Hobbs

List of Publications by Year
in descending order

65 papers	2,610 citations	257429 24 h-index	214788 47 g-index
66 all docs	66 docs citations	66 times ranked	3138 citing authors

#	Article	IF	Citations
1	Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics, 2014, 13, 41-54.	1.3	340
2	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respiratory Medicine,the, 2021, 9, 467-475.	10.7	277
3	Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials. Biometrics, 2011, 67, 1047-1056.	1.4	250
4	Time to initial cancer treatment in the United States and association with survival over time: An observational study. PLoS ONE, 2019, 14, e0213209.	2.5	179
5	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. Journal of Clinical Oncology, 2020, 38, 1569-1579.	1.6	158
6	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiotherapy and Oncology, 2018, 128, 154-160.	0.6	109
7	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Scientific Reports, 2018, 8, 1922.	3.3	108
8	Adaptive adjustment of the randomization ratio using historical control data. Clinical Trials, 2013, 10, 430-440.	1.6	86
9	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. Lancet Oncology, The, 2019, 20, 1386-1394.	10.7	69
10	Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. International Journal of Particle Therapy, 2017, 4, 23-32.	1.8	69
11	Bayesian basket trial design with exchangeability monitoring. Statistics in Medicine, 2018, 37, 3557-3572.	1.6	67
12	Controlled multi-arm platform design using predictive probability. Statistical Methods in Medical Research, 2018, 27, 65-78.	1.5	65
13	Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. , 2021, 9, e001719.		62
14	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	27.6	60
15	Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. Intensive Care Medicine, 2017, 43, 785-794.	8.2	55
16	Bayesian hierarchical modeling based on multisource exchangeability. Biostatistics, 2018, 19, 169-184.	1.5	49
17	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	6.3	49
18	Increased incidence of venous thromboembolism with cancer immunotherapy. Med, 2021, 2, 423-434.e3.	4.4	46

#	Article	IF	Citations
19	Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80ÂYears Old. International Journal of Radiation Oncology Biology Physics, 2017, 98, 811-819.	0.8	41
20	A Multi-Source Adaptive Platform Design for Testing Sequential Combinatorial Therapeutic Strategies. Biometrics, 2018, 74, 1082-1094.	1.4	38
21	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. Journal of Thoracic Oncology, 2020, 15, 101-109.	1.1	38
22	Moving Beyond 3+3: The Future of Clinical Trial Design. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e133-e144.	3.8	33
23	Bayesian Group Sequential Clinical Trial Design Using Total Toxicity Burden and Progression-Free Survival. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 273-297.	1.0	32
24	Phase II study of Dovitinib in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 144, 359-368.	2.9	29
25	Metastases to the Liver from Neuroendocrine Tumors: Effect of Duration of Scan Acquisition on CT Perfusion Values. Radiology, 2013, 269, 758-767.	7.3	27
26	Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis. Scientific Reports, 2019, 9, 18126.	3.3	26
27	Spatial Bayesian modeling of GLCM with application to malignant lesion characterization. Journal of Applied Statistics, 2019, 46, 230-246.	1.3	23
28	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. , 2019, 7, 127.		23
29	Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 4985-4994.	1.5	17
30	The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers, 2022, 14, 1304.	3.7	17
31	Current status and application of proton therapy for esophageal cancer. Radiotherapy and Oncology, 2021, 164, 27-36.	0.6	13
32	Bayesian Predictive Modeling for Genomic Based Personalized Treatment Selection. Biometrics, 2016, 72, 575-583.	1.4	12
33	Web-based statistical tools for the analysis and design of clinical trials that incorporate historical controls. Computational Statistics and Data Analysis, 2018, 127, 50-68.	1.2	12
34	Combining nonexchangeable functional or survival data sources in oncology using generalized mixture commensurate priors. Annals of Applied Statistics, 2015, 9, 1549-1570.	1.1	11
35	Basket Designs: Statistical Considerations for Oncology Trials. JCO Precision Oncology, 2019, 3, 1-9.	3.0	11
36	Basket Trials: Review of Current Practice and Innovations for Future Trials. Journal of Clinical Oncology, 2022, 40, 3520-3528.	1.6	10

#	ARTICLE	IF	CITATIONS
37	The promise and challenges of deep learning models for automated histopathologic classification and mutation prediction in lung cancer. Journal of Thoracic Disease, 2019, 11, 369-372.	1.4	9
38	The Diminishing Impact of Margin Definitions and Width on Local Recurrence Rates following Breast-Conserving Therapy for Early-Stage Invasive Cancer: A Meta-Analysis. Annals of Surgical Oncology, 2020, 27, 4628-4636.	1.5	9
39	Statistical design considerations for trials that study multiple indications. Statistical Methods in Medical Research, 2021, 30, 785-798.	1.5	9
40	Predictive classification of correlated targets with application to detection of metastatic cancer using functional CT imaging. Biometrics, 2015, 71, 792-802.	1.4	7
41	Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants. Biometrical Journal, 2019, 61, 902-917.	1.0	7
42	Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. JCO Clinical Cancer Informatics, 2021, 5, 1044-1053.	2.1	7
43	Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Statistical Methods in Medical Research, 2018, 27, 2093-2113.	1.5	4
44	Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis. Clinical Breast Cancer, 2020, 20, e625-e650.	2.4	4
45	A survival mediation model with Bayesian model averaging. Statistical Methods in Medical Research, 2021, 30, 2413-2427.	1.5	4
46	Bayesian basket trial design with false-discovery rate control. Clinical Trials, 2022, , 174077452110736.	1.6	4
47	A functional model for classifying metastatic lesions integrating scans and biomarkers. Statistical Methods in Medical Research, 2020, 29, 137-150.	1.5	3
48	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Statistics in Medicine, 2022, 41, 751-768.	1.6	3
49	A Bayesian nonparametric model for textural pattern heterogeneity. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 459-480.	1.0	2
50	The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. Blood, 2019, 134, 16-16.	1.4	2
51	Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?. Blood, 2019, 134, 381-381.	1.4	2
52	Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. JCO Precision Oncology, 2022, 6, e2100390.	3.0	2
53	Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. International Journal of Radiation Oncology Biology Physics, 2020, 107, 1001-1005.	0.8	1
54	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. Blood, 2018, 132, 4806-4806.	1.4	1

#	Article	IF	Citations
55	How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS. Blood, 2019, 134, 1716-1716.	1.4	1
56	Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.. Journal of Clinical Oncology, 2019, 37, 1032-1032.	1.6	1
57	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. Blood, 2019, 134, 2595-2595.	1.4	1
58	Calibrated dynamic borrowing using capping priors. Journal of Biopharmaceutical Statistics, 2021, 31, 852-867.	0.8	1
59	Estimating mean local posterior predictive benefit for biomarker-guided treatment strategies. Statistical Methods in Medical Research, 2019, 28, 2820-2833.	1.5	0
60	Comparing phase 3 â€œgoâ€•decisions (Ph3-GO) between single arm trials with real-world external control (SAT+rwEC) versus randomized phase 2 trials (rPh2).. Journal of Clinical Oncology, 2021, 39, e13564-e13564.	1.6	0
61	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. Blood, 2018, 132, 1527-1527.	1.4	0
62	Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies. Blood, 2019, 134, 3433-3433.	1.4	0
63	Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients. Blood, 2019, 134, 3836-3836.	1.4	0
64	A groupâ€sequential randomized trial design utilizing supplemental trial data. Statistics in Medicine, 2021, , .	1.6	0
65	An 11-gene expression signature related to tumorigenesis and immunosuppression in primary cutaneous melanoma predicts sentinel lymph node metastatic status.. Journal of Clinical Oncology, 2022, 40, e21579-e21579.	1.6	0